Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
New model of neuronal circuit provides insight on eye movement
Working with week-old zebrafish larva, researchers at Weill Cornell Medicine and colleagues decoded how the connections formed by a network of neurons in the brainstem guide the fishes’ gaze. The…
Innovative protocol maps NMDA receptors in Alzheimer’s-Affected brains
Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of…
New insights into sleep
…uncover key mechanisms related to cognitive function. Discovery suggests broad implications for giving brain a boost. While it’s well known that sleep enhances cognitive performance, the underlying neural mechanisms, particularly…